When preparing to obtain an EU GMP certificate and register medicinal products in the European market, pharmaceutical manufacturers must comply with strict requirements related to raw materials, batch documentation, quality control analysis, and regulatory inspection procedures. These elements are essential for demonstrating that the manufacturing facility can consistently produce safe and high-quality pharmaceutical products.

In practice, achieving EU GMP compliance also depends heavily on facility infrastructure such as cleanrooms, HVAC systems, airlocks, pass boxes, and environmental monitoring equipment. These technical systems help maintain controlled production environments and are often implemented with specialized engineering solutions from suppliers such as thiết bị phòng sạch VCR (Vietnam Cleanroom Equipment). The following FAQ explains common regulatory questions related to raw materials, production documentation, and EU GMP inspection preparation.

Must the API manufacturer be declared in the EU marketing authorization dossier?

In the European pharmaceutical regulatory system, the manufacturer of the active pharmaceutical ingredient (API) must be declared before the start of commercial production. This information is typically included in the dossier submitted for marketing authorization in the European Union.

Regulatory authorities may request detailed information about the API manufacturer during the registration process. The purpose of this requirement is to ensure transparency in the pharmaceutical supply chain and confirm that the raw materials used in drug production meet appropriate quality and GMP standards. During an EU GMP inspection, inspectors may verify the declared API manufacturer as part of the overall evaluation of the manufacturing system and raw material supply chain.

Do excipient manufacturers also need to comply with GMP in EU registration?

For medicinal products registered in the European Union, manufacturers of raw materials including APIs and excipients must meet appropriate quality and regulatory requirements. In particular, API manufacturers must comply with GMP because the active ingredient directly determines the therapeutic effectiveness of the medicinal product.

For excipients, authorities may require evidence that the manufacturer operates under an appropriate quality management system and maintains traceable production processes. During EU GMP inspections, inspectors may review supplier qualification records, supplier audit procedures, and raw material control systems to ensure that the pharmaceutical manufacturer maintains proper oversight of the supply chain.

What documents must be prepared for EU GMP inspection of pharmaceutical products?

During an EU GMP inspection, the manufacturing facility must provide comprehensive documentation demonstrating control over the production and quality assurance processes. Important documents typically include batch manufacturing records, quality control analysis reports, and documentation related to the manufacturing process.

Inspectors do not evaluate only the regulatory dossier but also examine the complete production documentation for the selected products. This allows them to confirm that the actual manufacturing practices correspond to the information declared in the regulatory dossier and comply with GMP standards.

Is it necessary to produce batches before an EU GMP inspection?

Before an EU GMP inspection takes place, the pharmaceutical manufacturer should complete at least one production batch for each product that is expected to be included in the inspection scope. This batch must include full batch documentation, analytical testing results, and all associated quality records.

In practice, demonstrating three production batches is strongly recommended because it provides stronger evidence that the manufacturing process is stable and reproducible. Data from multiple batches allow inspectors to evaluate the reliability of the production system and confirm that the manufacturing process can consistently produce products meeting the required specifications.

What aspects of production will EU GMP inspectors evaluate?

During an EU GMP inspection, inspectors examine the entire pharmaceutical manufacturing system. This includes production lines, quality control laboratories, documentation systems, batch records, and operational procedures.

Inspectors may also review production activities that are currently running during the inspection. Observing real manufacturing operations allows them to assess whether daily practices follow documented procedures and comply with GMP regulations. Active production during inspection often provides inspectors with a clearer understanding of how the facility operates under real conditions.

What is the role of the MIA partner in the EU pharmaceutical supply chain?

Within the European pharmaceutical regulatory framework, the MIA partner is the organization responsible for importing medicinal products from countries outside the European Union into the EU market. This organization holds a Manufacturing Import Authorization and ensures that imported medicines meet regulatory and GMP requirements.

The MIA partner also acts as an important regulatory interface between the manufacturing site and European authorities. Their responsibilities may include coordinating regulatory documentation, ensuring compliance with EU standards, and managing import control procedures for pharmaceutical products entering the European market.

Why does the MIA partner influence EU GMP inspection preparation?

The MIA partner often plays a significant role in coordinating activities between the pharmaceutical manufacturer and the European regulatory environment. Because the MIA organization is responsible for importing and distributing the medicinal product within the EU, it must ensure that the manufacturing facility complies with EU GMP standards.

In many projects, the MIA partner participates in preparing for the inspection, coordinating communication with regulatory authorities, and helping organize inspection schedules. Without proper collaboration with the MIA partner, arranging EU GMP inspections and managing regulatory communication may become more difficult.

Why is close collaboration with EU partners important before GMP inspection?

Working closely with European regulatory and commercial partners helps pharmaceutical manufacturers better understand EU regulatory expectations and prepare effectively for GMP inspections. These partners often have experience working with European regulatory authorities and can provide guidance on documentation, inspection preparation, and regulatory procedures.

In addition, EU partners may act as importers, distributors, or market authorization holders. Their involvement ensures that the pharmaceutical product can successfully enter the European market after GMP certification is obtained. Effective collaboration between the manufacturer and European partners significantly increases the likelihood of successful inspection and product registration

DAP

Tags: